Antharis Therapeutics Announces Successful Close of Their Series A.

SAN DIEGO—Antharis Therapeutics Inc., a biopharmaceutical company developing a leading portfolio of oncology- and neurology-related immunotherapeutics, announced the completion of their Series A funding today. The jump in valuation places the company at the leading edge of biotechnology companies generating high-potential biologic assets for the treatment of significant diseases in multiple therapeutic classes.

“Antharis is very pleased by our recent valuation jump validating not only the power of our platform but the significance of the validated assets in our pipeline,” said Dr. Raphael Ribeiro-Pinaud, CEO of Antharis Therapeutics.

Antharis leverages a unique platform for the discovery, characterization, and validation of monoclonal antibody assets across the oncology and neurology therapeutic areas. The company’s unique view of immunotherapy and highly specialized platform have delivered successfully validated in vivo assets at a significantly higher rate than the industry norm. This has allowed Antharis to grow one of the largest preclinical portfolios in the industry and supported the company’s recent acquisition of Cassyni Biopharma in July 2022. Antharis will begin pre-IND work on a selection of their assets this year.

About Antharis Therapeutics

Antharis Therapeutics Inc. is a biopharmaceutical company involved in the discovery and development of immunotherapeutics to address devastating diseases for which there are limited or unsatisfactory treatment options. Antharis is focused on oncological (cancer) and neurological disease (brain) diseases, as these are two of the largest markets in need of therapies and where our team has its greatest expertise, and the Antharis platform has facilitated unprecedented growth in validated portfolio assets. Antharis is based in San Diego, California, at the heart of the Life Sciences Cluster (LSC), one of the prime biotechnology hubs in the world and is operated by Dr. Raphael Ribeiro-Pinaud, CEO. For more information, please visit https://antharistherapeutics.com/